투자판단관련주요경영사항(임상시험결과) (나이벡 펩타이드 NP201 호주 임상 1b 임상시험결과)[코]
Received: 1/29/2026 · Reporter: 나이벡
A summary for this filing type is not yet available. Please refer to the original DART filing.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 14 filings
- Same category
- 8 filings
- Previous same-category filing
- 5/18/2026
- Corrections / withdrawals
- 1 filing
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).